Janet Napolitano Sells 3,200 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total transaction of $30,240.00. Following the transaction, the director directly owned 21,216 shares in the company, valued at $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vir Biotechnology Stock Performance

VIR stock opened at $8.77 on Thursday. The company has a market capitalization of $1.48 billion, a PE ratio of -2.80 and a beta of 1.65. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $11.66. The company’s 50 day moving average price is $9.49 and its two-hundred day moving average price is $8.00.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The firm had revenue of ($0.03) million during the quarter, compared to analysts’ expectations of $55.49 million. During the same period in the previous year, the firm earned ($0.88) earnings per share. On average, research analysts predict that Vir Biotechnology, Inc. will post -1.81 EPS for the current year.

Institutional Trading of Vir Biotechnology

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after buying an additional 1,390 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Vir Biotechnology during the 3rd quarter valued at $38,000. Raymond James Financial Inc. bought a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $35,000. UMB Bank n.a. boosted its holdings in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after buying an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after buying an additional 4,899 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Analysts Set New Price Targets

VIR has been the topic of several analyst reports. Barclays lifted their target price on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. Morgan Stanley set a $23.00 target price on shares of Vir Biotechnology in a research note on Friday, May 8th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a research note on Tuesday, February 24th. Leerink Partners lifted their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Needham & Company LLC lifted their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.38.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.